{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:04:52Z","timestamp":1790355892434,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T00:00:00Z","timestamp":1551052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UM Lipodystrophy Fund"},{"name":"White Point Foundation of Turkey"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT 107064"],"award-info":[{"award-number":["WT 107064"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MRC Metabolic Disease Unit","award":["MRC_MC_UU_12012.1"],"award-info":[{"award-number":["MRC_MC_UU_12012.1"]}]},{"name":"The National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre"},{"name":"NIHR Rare Disease Translational Research Collaboration"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12020-019-01862-8","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T14:59:54Z","timestamp":1551106794000},"page":"500-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy"],"prefix":"10.1007","volume":"64","author":[{"given":"Elif A.","family":"Oral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Gorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Salinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,25]]},"reference":[{"issue":"12","key":"1862_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"R.J. Brown, D. Araujo-Vilar, P.T. Cheung, D. Dunger, A. Garg, M. Jack, L. Mungai, E.A. Oral, N. Patni, K.I. Rother, J. von Schnurbein, E. Sorkina, T. Stanley, C. Vigouroux, M. Wabitsch, R. Williams, T. Yorifuji, The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J. Clin. Endocrinol. Metab. 101(12), 4500\u20134511 (2016). \n                    https:\/\/doi.org\/10.1210\/jc.2016-2466","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"1862_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","volume":"19","author":"Y Handelsman","year":"2013","unstructured":"Y. Handelsman, E.A. Oral, Z.T. Bloomgarden, R.J. Brown, J.L. Chan, D. Einhorn, A.J. Garber, A. Garg, W.T. Garvey, G. Grunberger, R.R. Henry, N. Lavin, C.D. Tapiador, C. Weyer, The clinical approach to the detection of lipodystrophy \u2013 an AACE consensus statement. Endocr. Pract. 19(1), 107\u2013116 (2013)","journal-title":"Endocr. Pract."},{"issue":"12","key":"1862_CR3","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"A. Garg, Acquired and inherited lipodystrophies. New. Engl. J. Med. 350(12), 1220\u20131234 (2004). \n                    https:\/\/doi.org\/10.1056\/NEJMra025261","journal-title":"New. Engl. J. Med."},{"key":"1862_CR4","doi-asserted-by":"publisher","unstructured":"D. Ara\u00fajo-Vilar, F. Santini, Diagnosis and treatment of lipodystrophy: a step-by-step approach. J. Endocrinol. Invest., \n                    https:\/\/doi.org\/10.1007\/s40618-40018-40887-z.\n                    \n                   [e-pub ahead of print] (2018).","DOI":"10.1007\/s40618-40018-40887-z."},{"issue":"2","key":"1862_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s12020-016-1002-x","volume":"54","author":"C Guill\u00edn-Amarelle","year":"2016","unstructured":"C. Guill\u00edn-Amarelle, S. S\u00e1nchez-Iglesias, A. Castro-Pais, L. Rodriguez-Ca\u00f1ete, L. Ord\u00f3\u00f1ez-May\u00e1n, M. Pazos, B. Gonz\u00e1lez-M\u00e9ndez, S. Rodr\u00edguez-Garc\u00eda, F.F. Casanueva, A. Fern\u00e1ndez-Marmiesse, D. Ara\u00fajo-Vilar, Type 1 familial partial lipodystrophy: understanding the Kobberling syndrome. Endocrine 54(2), 411\u2013421 (2016). \n                    https:\/\/doi.org\/10.1007\/s12020-016-1002-x","journal-title":"Endocrine"},{"key":"1862_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"B. Akinci, H. Onay, T. Demir, S. Savas-Erdeve, R. Gen, I.Y. Simsir, F.E. Keskin, M.S. Erturk, A.K. Uzum, G.F. Yaylali, N.K. Ozdemir, T. Atik, S. Ozen, B.S. Yurekli, T. Apaydin, C. Altay, G. Akinci, L. Demir, A. Comlekci, M. Secil, E.A. Oral, Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. Metab. Clin. Exp. 72, 109\u2013119 (2017). \n                    https:\/\/doi.org\/10.1016\/j.metabol.2017.04.010","journal-title":"Metab. Clin. Exp."},{"issue":"11","key":"1862_CR7","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"A. Garg, Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96(11), 3313\u20133325 (2011). \n                    https:\/\/doi.org\/10.1210\/jc.2011-1159","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"1862_CR8","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1210\/jcem.85.5.6605","volume":"85","author":"A Garg","year":"2000","unstructured":"A. Garg, Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 85(5), 1776\u20131782 (2000). \n                    https:\/\/doi.org\/10.1210\/jcem.85.5.6605","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"1862_CR9","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.3390\/nu7115475","volume":"7","author":"C Saponaro","year":"2015","unstructured":"C. Saponaro, M. Gaggini, F. Carli, A. Gastaldelli, The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients 7(11), 9453\u20139474 (2015). \n                    https:\/\/doi.org\/10.3390\/nu7115475","journal-title":"Nutrients"},{"issue":"9","key":"1862_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2015.123","volume":"11","author":"N Patni","year":"2015","unstructured":"N. Patni, A. Garg, Congenital generalized lipodystrophies\u2014new insights into metabolic dysfunction. Nat. Rev. Endocrinol. 11(9), 522\u2013534 (2015). \n                    https:\/\/doi.org\/10.1038\/nrendo.2015.123","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"1862_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/17512433.2016.1096772","volume":"9","author":"CA Meehan","year":"2016","unstructured":"C.A. Meehan, E. Cochran, A. Kassai, R.J. Brown, P. Gorden, Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Exp. Rev. Clin. Pharmacol. 9(1), 59\u201368 (2016). \n                    https:\/\/doi.org\/10.1586\/17512433.2016.1096772","journal-title":"Exp. Rev. Clin. Pharmacol."},{"issue":"1","key":"1862_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1023\/A:1021827520301","volume":"4","author":"EA Oral","year":"2003","unstructured":"E.A. Oral, Lipoatrophic diabetes and other related syndromes. Rev. Endocr. Metab. Dis. 4(1), 61\u201377 (2003)","journal-title":"Rev. Endocr. Metab. Dis."},{"issue":"5","key":"1862_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2014-4491","volume":"100","author":"T Diker-Cohen","year":"2015","unstructured":"T. Diker-Cohen, E. Cochran, P. Gorden, R.J. Brown, Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. J. Clin. Endocrinol. Metab. 100(5), 1802\u20131810 (2015). \n                    https:\/\/doi.org\/10.1210\/jc.2014-4491","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"1862_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.metabol.2015.06.004","volume":"64","author":"B Akinci","year":"2015","unstructured":"B. Akinci, F.D. Koseoglu, H. Onay, S. Yavuz, C. Altay, I.Y. Simsir, S. Ozisik, L. Demir, M. Korkut, N. Yilmaz, S. Ozen, G. Akinci, T. Atik, M. Calan, M. Secil, A. Comlekci, T. Demir, Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metab. Clin. Exp. 64(9), 1086\u20131095 (2015). \n                    https:\/\/doi.org\/10.1016\/j.metabol.2015.06.004","journal-title":"Metab. Clin. Exp."},{"key":"1862_CR15","unstructured":"Myalept [Package Insert]. (Aegerion Pharmaceuticals, Inc., Cambridge, 2015) \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125390s000lbl.pdf"},{"key":"1862_CR16","unstructured":"Myalepta; Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004218\/WC500253136.pdf\n                    \n                   (2018). Accessed 14 Jan 14 2019"},{"issue":"6","key":"1862_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4158\/EP11229.OR","volume":"17","author":"JL Chan","year":"2011","unstructured":"J.L. Chan, K. Lutz, E. Cochran, W. Huang, Y. Peters, C. Weyer, P. Gorden, Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17(6), 922\u2013932 (2011). \n                    https:\/\/doi.org\/10.4158\/ep11229.or","journal-title":"Endocr. Pract."},{"issue":"1","key":"1862_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","volume":"53","author":"AY Chong","year":"2010","unstructured":"A.Y. Chong, B.C. Lupsa, E.K. Cochran, P. Gorden, Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53(1), 27\u201335 (2010). \n                    https:\/\/doi.org\/10.1007\/s00125-009-1502-9","journal-title":"Diabetologia"},{"issue":"8","key":"1862_CR19","doi-asserted-by":"publisher","first-page":"E1493","DOI":"10.1210\/jc.2014-1353","volume":"99","author":"JD Christensen","year":"2014","unstructured":"J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99(8), E1493\u2013E1500 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-1353","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"1862_CR20","doi-asserted-by":"publisher","first-page":"E1676","DOI":"10.1210\/jc.2014-1878","volume":"99","author":"J Joseph","year":"2014","unstructured":"J. Joseph, R.D. Shamburek, E.K. Cochran, P. Gorden, R.J. Brown, Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. J. Clin. Endocrinol. Metab. 99(9), E1676\u2013E1680 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-1878","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5-6","key":"1862_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000341398","volume":"78","author":"F Kamran","year":"2012","unstructured":"F. Kamran, K.I. Rother, E. Cochran, E. Safar Zadeh, P. Gorden, R.J. Brown, Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm. Res. Paediatr. 78(5-6), 320\u2013325 (2012). \n                    https:\/\/doi.org\/10.1159\/000341398","journal-title":"Horm. Res. Paediatr."},{"issue":"2","key":"1862_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jacl.2017.02.002","volume":"11","author":"R Muniyappa","year":"2017","unstructured":"R. Muniyappa, B.S. Abel, A. Asthana, M.F. Walter, E.K. Cochran, A.T. Remaley, M.C. Skarulis, P. Gorden, R.J. Brown, Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. J. Clin. Lipidol. 11(2), 543\u2013550 (2017). \n                    https:\/\/doi.org\/10.1016\/j.jacl.2017.02.002","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"1862_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","volume":"60","author":"RJ Brown","year":"2018","unstructured":"R.J. Brown, E.A. Oral, E. Cochran, D. Araujo-Vilar, D.B. Savage, A. Long, G. Fine, T. Salinardi, P. Gorden, Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine 60(3), 479\u2013489 (2018). \n                    https:\/\/doi.org\/10.1007\/s12020-018-1589-1","journal-title":"Endocrine"},{"issue":"8","key":"1862_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"E.A. Oral, V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A.J. Wagner, A.M. DePaoli, M.L. Reitman, S.I. Taylor, P. Gorden, A. Garg, Leptin-replacement therapy for lipodystrophy. New. Engl. J. Med. 346(8), 570\u2013578 (2002). \n                    https:\/\/doi.org\/10.1056\/NEJMoa012437","journal-title":"New. Engl. J. Med."},{"issue":"7","key":"1862_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/dom.12606","volume":"18","author":"C Vatier","year":"2016","unstructured":"C. Vatier, S. Fetita, P. Boudou, C. Tchankou, L. Deville, J. Riveline, J. Young, L. Mathivon, F. Travert, D. Morin, J. Cahen, O. Lascols, F. Andreelli, Y. Reznik, E. Mongeois, I. Madelaine, M. Vantyghem, J. Gautier, C. Vigouroux, One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes. Metab. 18(7), 693\u2013697 (2016). \n                    https:\/\/doi.org\/10.1111\/dom.12606","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"1862_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1210\/jc.2011-2229","volume":"97","author":"V Simha","year":"2012","unstructured":"V. Simha, L. Subramanyam, L. Szczepaniak, C. Quittner, B. Adams-Huet, P. Snell, A. Garg, Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab. 97(3), 785\u2013792 (2012). \n                    https:\/\/doi.org\/10.1210\/jc.2011-2229","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"1862_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4172\/2155-6156.1000659","volume":"7","author":"N Ajluni","year":"2016","unstructured":"N. Ajluni, M. Dar, J. Xu, A.H. Neidert, E.A. Oral, Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J. Diabetes Metab. 7(3), 659 (2016). \n                    https:\/\/doi.org\/10.4172\/2155-6156.1000659","journal-title":"J. Diabetes Metab."},{"key":"1862_CR28","unstructured":"A. Garg, National Organization for Rare Disorders (NORD): Familial partial lipodystrophy. \n                    https:\/\/rarediseases.org\/rare-diseases\/familial-partial-lipodystrophy\/\n                    \n                   (2015). Accessed 4 Oct 2017"},{"key":"1862_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2147\/DMSO.S130810","volume":"10","author":"E Chiquette","year":"2017","unstructured":"E. Chiquette, E.A. Oral, A. Garg, D. Araujo-Vilar, P. Dhankhar, Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab. Syndr. Obes. 10, 375\u2013383 (2017). \n                    https:\/\/doi.org\/10.2147\/DMSO.S130810","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-01862-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01862-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:20:17Z","timestamp":1589894417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-01862-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1862"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-01862-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E.A.O. has served as a consultant to Aegerion Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Regeneron Therapeutics, and Thera Therapeutics; has received grant support from Aegerion Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Gemphire Therapeutics, GIDynamics, and Ionis Pharmaceuticals; and has received nonmaterial support from Aegerion Pharmaceuticals and Boehringer Ingelheim. D.A.V. and D.B.S. have served as consultants to Aegerion Pharmaceuticals. A.L. and T.S. are former employees and G.F. is a current employee of Aegerion Pharmaceuticals. E.C., P.G., and R.B. report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice and was approved by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseases institutional review boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients or their legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}